Cardiff’s onvansertib is being trialed in a phase 1b/2 study in patients with metastatic colorectal cancer who have a mutation of the KRAS gene, according to a Wednesday release. The therapy is being combined with chemotherapy and Roche’s stalwart Avastin. Patients must have failed on chemotherapy and or/Avastin prior to entry in the trial.